New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial Resolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test